Report Overview

The Kenya Pain Management drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Pain is an uncomfortable sensory stimulation to the nervous system. It can be described as throbbing, pinching, stinging or burning. Pain can be acute or chronic. Acute pain is sudden onset that can last up to days and Chronic pain is persistent pain that can last up to months or years. On the basis of origin of the pain, it can be nociceptive pain (result of tissue damage/injury), inflammatory pain (inflammation caused by response of immune system) and neuropathic pain (caused dur to nerve irritation). Pain Management is an important in post-operative cases. The Most common surgical procedures performed in Kenya are caesarean section, tubal ligation, explorative laparotomy, eye/lens removal and hernia repair. Opioids like Morphine is commonly prescribed to treat pain in patients suffering from terminal stage cancers.



Market Drivers

The market is majorly driven by the surge in chronic diseases like osteoarthritis, cancers and diabetic neuropathy. The five most common cancers in Kenya are Breast, Cervical, Prostate, Oesophagus and Colorectal Cancer. Mastectomy (surgical removal of breast tissues) is a treatment option in breast cancer to prevent metastasis of the cancer. Osteoarthritis is the most common rheumatologic condition and requires pain killers as a part of the treatment.

Presence of strong pipeline products in the market drives the pain management drugs market growth.

Moreover, increase in research and development investments and rise in outsourcing of pharmaceuticals are expected to fuel the market growth.

Rise in number of drug abuse cases and addictive nature of opioids has decreased use of prescriptions for opioids in the region, leading to decline in opioid consumption for pain management.